January 3, 2017 / 1:11 PM / a year ago

BRIEF-Inotek announces top-line results for MATRX-1

Jan 3 (Reuters) - Inotek Pharmaceuticals Corp :

* Inotek announces top-line results for matrx-1, first phase 3 trial of trabodenoson for glaucoma

* Inotek pharmaceuticals corp - trial did not achieve superiority to placebo at all 12 time points

* Inotek pharmaceuticals corp - no significant safety or tolerability events reported. Safety profile of trabodenoson was comparable to placebo

* Inotek pharmaceuticals corp - results of fdc phase 2 trial, which is substantially enrolled and for which we expect to report top-line data mid-year

* Inotek Pharmaceuticals corp - 4 subjects (2.2%) discontinued trial due to a treatment-related adverse event Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below